Eric Ostertag, M.D., Ph.D., is a key figure in the biotechnology world, having led Poseida Therapeutics as the CEO before becoming the Executive Chairman. His educational background is impressive; he holds both an M.D. and a Ph.D. from the University...

Eric Ostertag, M.D., Ph.D., is a key figure in the biotechnology world, having led Poseida Therapeutics as the CEO before becoming the Executive Chairman. His educational background is impressive; he holds both an M.D. and a Ph.D. from the University of California, San Diego. Under his leadership, Poseida Therapeutics focused on innovative treatments in genetic therapies and cell therapy, aiming to change the standard of care in the industry. Eric is also a savvy investor, having made significant insider trades, including transactions that have moved millions in worth, particularly in 2021, when he traded stocks valued over $41 million in a single month. Despite stepping down as CEO in early 2022, he continues to influence Poseida’s strategic direction and scientific advancements. His unique blend of medical knowledge and business acumen positions him as a significant player not only in biotech but also in investment circles. His transition to Executive Chairman didn't change his hands-on approach to guiding the company through its next stages. With a vested interest in Poseida’s success, he plans to continue contributing to the company's research and innovation goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Poseida Therapeutics, Inc. CEOs

P

Eric Ostertag, M.D., Ph.D.

Founder and Ex-CEO of Poseida Therapeutics, Inc.

Education

M.D. and Ph.D. from the University of California, San Diego

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of Poseida Therapeutics, Inc. for

3 years 1 month (Jan 2019 - Feb 2022)

Previous Experience

Co-founder and CEO of Poseida Therapeutics, Inc.

Rivals

Competitors/colleagues of Eric Ostertag, M.D., Ph.D.

Holdings

See how much did Eric Ostertag, M.D., Ph.D. make over time.

As of March 2022, Eric Ostertag holds approximately 15.3% of Poseida Therapeutics, comprising around 9.6 million shares. Notably, he had fluctuated between significant stock holdings in the company, with his ownership level peaking as companies often assess their leaders based...

As of March 2022, Eric Ostertag holds approximately 15.3% of Poseida Therapeutics, comprising around 9.6 million shares. Notably, he had fluctuated between significant stock holdings in the company, with his ownership level peaking as companies often assess their leaders based on their personal investment in the firm. Back in 2020, at different points, he sold shares totaling over $10 million in value. In 2021, his sales further surged, hitting over $41 million in value just in one month, showcasing both confidence and strategy in managing his assets. Even after stepping down as CEO, he continues to keep a substantial stake in the company, highlighting his belief in Poseida’s future growth and potential.

Total Stock Sold

$8.07M

PSTX

$8.07M

950,066 PSTX shares

What if they kept their stock?

If Eric Ostertag, M.D., Ph.D. didn't sell their stock, today they would have:
Extra PSTX950,066 shares worth $14.58M.
This is 80.75% and $6.52M more than what they got when they sold the stock.

Charitable Transactions

PSTX

142,857 shares

PSTX

Recent Charitable Transactions

PSTX

142,857 shares

PSTX

Feb 1, 2022

Charity

Insider Trading

See recent insider trades of Eric Ostertag, M.D., Ph.D..

PSTX

$500.00K

PSTX at $3.50/share

Aug 8, 2022

Purchase

PSTX

$592.81K

PSTX at $3.69/share

Aug 3, 2022

Sale

PSTX

89,500 shares

PSTX

Feb 1, 2022

Received

PSTX

142,857 shares

PSTX

Feb 1, 2022

Charity

PSTX

$134.17K

PSTX at $7.09/share

Nov 8, 2021

Sale

PSTX

$140.60K

PSTX at $7.02/share

Oct 1, 2021

Sale

PSTX

$160.02K

PSTX at $8.00/share

Sep 20, 2021

Sale

PSTX

$162.71K

PSTX at $8.14/share

Sep 13, 2021

Sale

PSTX

$944.25K

PSTX at $8.40/share

Sep 1, 2021

Sale

PSTX

$271.40K

PSTX at $8.06/share

Aug 2, 2021

Sale

Compensation History

See how much did Eric Ostertag, M.D., Ph.D. make over time.

In 2022, Eric Ostertag's reported total compensation as Executive Chairman was approximately $461,000, with a salary of around $448,000. After transitioning from CEO to this new role, incentive-based bonuses no longer applied to him, and he navigated this transition without any stock grants. In earlier years, his total compensation peaked at over $6.4 million in 2021, largely due to a performance-based bonus tied to company achievements. His compensation package included options and salary adjustments, reflecting the biotech sector's highly competitive landscape and the need to attract and retain capable leaders capable of driving innovation. Although his pay has adjusted with his role change, his longstanding commitment to Poseida remains evident, further demonstrated by his extensive stock holdings. This pay structure aligns with industry standards while supporting long-term company objectives.

Year

2022

Total Compensation

$461.02K

Salary

$448.31K

Board Justification

The compensation philosophy aligns with company performance and peer benchmarking, focusing on retention strategies for key executives.

Bonus

$0.00

Board Justification

Dr. Ostertag was no longer eligible for a performance bonus after transitioning to Executive Chairman in February 2022.

Other

$12.71K

Board Justification

Other compensation includes 401(k) matching contributions and life insurance premiums.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2022 as he transitioned to Executive Chairman and did not receive stock grants during this period.

Performance Metrics

Performance metrics were not applicable for Dr. Ostertag in 2022 as he was no longer eligible for performance-based bonuses.

Other Poseida Therapeutics, Inc. CEOs

Here are other CEOs of Poseida Therapeutics, Inc.

Mark Gergen

Ex-CEO of Poseida Therapeutics, Inc.

February 2022 - October 2023